Brief: Grand Pharmaceutical Says Drug Achieved Clinical Study Endpoint Of Phase Ib Trial In China
31/10/2022 10:24
Oct 31 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* DRUG STC3141 SUCCESSFULLY ACHIEVED CLINICAL STUDY ENDPOINT
OF
PHASE IB CLINICAL TRIAL IN CHINA
Source text for Eikon: ID:nHKS6hnLZt
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement